Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

NICE Rejects Bayer And Eisai Drugs In Thyroid Cancer

(Pharmaphorum [UK]) Oct 20, 2017 - NICE wants to axe NHS funding for Bayer’s Nexavar and Eisai’s Lenvima, saying in draft guidance that neither is cost-effective in treating thyroid cancer.

Philadelphia Inquirer Op-ed Educates Patients, Highlights Physician Concerns Over Right-to-Try

(ASCO in Action) Oct 19, 2017 - On Thursday, October 19, The Philadelphia Inquirer published an op-ed by ASCO President Bruce E. Johnson, MD, FASCO, and Marilyn J. Heine, MD, legislative chair of the Pennsylvania Society of Oncology and Hematology (PSOH) on Pennsylvania’s new right-to-try (RTT) law.

Researchers To Combat Drug-Resistant Lung Cancer At New NCI-Funded Center At UCSF

(UC San Francisco) Oct 19, 2017 - The National Cancer Institute (NCI) has announced that UC San Francisco will host one of five new Cancer Drug Resistance and Sensitivity Centers being set up around the U.S. through funding from the 21st Century Cures Act of 2016.

NICE No For Opdivo In Urothelial Carcinoma

(PharmaTimes [UK]) Oct 20, 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

Cancer Patients at The Center for Cancer and Blood Disorders Advocate for Local Cancer Care

(COA) Oct 19, 2017 - As Community Oncology Clinics Are Threatened, Cancer Patients, Survivors Form CPAN Chapter to Speak Out

FDA Approval Of Lymphoma Therapy Shows Gilead’s Purchase Of Kite Was A Good Bet

(Los Angeles Times) Oct 19, 2017 - Gilead Sciences Inc.’s stock rose Thursday after the biotech company’s Kite Pharma unit gained federal approval for its flagship cell-treatment therapy for adults with advanced lymphoma.

Antimicrobial Resistance, And Lack Of New Drugs, Raises Risk Of A Global Pandemic

(Forbes) Oct 19, 2017 - Having killed at least 74 people in the last few weeks, the plague ravaging Madagascar has just jumped across the border and off the island.

With Obamacare, Fewer Americans Were Uninsured When They Were Told They Had Cancer

(Los Angeles Times) Oct 19, 2017 - As President Trump and his allies in Congress keep pushing to get rid of Obamacare, new research shows that the contentious law has succeeded in expanding health insurance coverage for Americans with cancer.

Celgene Abandons Crohn’s Drug Trials, Shares Drop

(Reuters) Oct 19, 2017 - Celgene Corp said it would abandon testing a drug to treat Crohn’s disease, in a major setback to the U.S. biotechnology company’s pipeline amid attempts to lower dependence on its mainstay Revilimid.

Suicide Molecules Kill Any Cancer Cell

(Northwestern University) Oct 19, 2017 - Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules to trigger a fail-safe mechanism that may protect us from cancer.